Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI Worldwide, MilanCPhI Worldwide, Milan
Not Confirmed
Not Confirmed
08-10 October, 2024
Discovery on TargetDiscovery on Target
Not Confirmed
Not Confirmed
30 September-03 October, 2024
Not Confirmed
Not Confirmed
30 September-02 October, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Not Confirmed
08-10 October, 2024
Discovery on TargetDiscovery on Target
Industry Trade Show
Not Confirmed
30 September-03 October, 2024
Industry Trade Show
Not Confirmed
30 September-02 October, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/ice-is-pioneering-sustainability-innovation-in-bile-acid-research-for-neurodegenerative-diseases
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/2024-us-elections-harris-trump-differ-on-abortion-rights-aca-public-health-spends-agree-on-need-to-cut-drug-prices
16 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/gv20-therapeutics-presents-promising-phase-1-monotherapy-data-on-novel-checkpoint-inhibitor-gv20-0251-at-esmo-congress-2024-302247149.html
21 Aug 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/gv20-therapeutics-to-present-clinical-data-on-gv20-0251-at-the-esmo-congress-2024-302225841.html
24 Apr 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/gv20-therapeutics-announces-publication-in-cell-highlighting-the-discovery-of-igsf8-as-an-innate-immune-checkpoint-and-cancer-immunotherapy-target-302126064.html
18 Apr 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/gv20-therapeutics-announces-clinical-trial-collaboration-to-evaluate-gv20-0251-a-first-in-class-antagonist-antibody-against-the-novel-immune-checkpoint-igsf8-in-combination-with-keytruda-pembrolizumab-302120896.html
08 Apr 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/gv20-therapeutics-presents-preclinical-data-on-gv20-0251-for-solid-tumors-targeting-igsf8-at-aacr-annual-meeting-2024-302110684.html
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?